Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: First in Human Study to Evaluate Safety of Cellavita HD Investigational Product After Intravenous Application in Participants With Huntington's Disease
Brief Summary: Cellavita HD is a stem-cell therapy for Huntington's Disease. This is a first-in-human, dose escalation study in which participants with Huntington's Disease will receive 3 intravenous injections and will be followed for 5 years to evaluate safety and preliminary evidence of effectiveness.